CRLCharles River Laboratories
Is the business good?
The checks split: earnings fully cash-backed (8.2×), but margins compressing.
Operating profit is fully backed by cash. Conversion is improving vs a year ago.
Operating margin has narrowed over the past few years, profitability per dollar of sales is eroding.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.
How good a business is CRL?
Charles River Laboratories earns 1.4% on the capital it employs against a 9.0% cost of capital, so growth costs more than it returns.
Return on invested capital · cost of capital 9.0% · 7.6 points below what the capital costs: growth destroys value
- Operating margin
- 2.3%
Operating margin · Diagnostics & Research median 3.6% · 12 months to Q2 2026
- Cash conversion
- 8.18×
Cash conversion · 8.01× a year ago · operating cash flow covers the operating profit after tax
- Share count, year on year
- −2.6%
Share count, year on year · bought back, each share owns more of the company
| Year | Operating margin |
|---|---|
| FY2020 | 15% |
| FY2021 | 17% |
| FY2022 | 16% |
| FY2023 | 15% |
| FY2024 | 5.6% |
| FY2025 | 0.63% |
Details›
- Operating margin12 months to Q2 2026
- 2.3%
- Net margin12 months to Q2 2026
- −6.0%
- Free cash flow margin
- 9.3%
- Revenue, trailing twelve months
- $4.00B
- Free cash flow, trailing twelve months
- $371M
- Net income, trailing twelve months
- −$238M
- Return on invested capitaloperating profit after tax ÷ debt + equity − cash
- 1.4%
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.
Diagnostics & Research
The closest names by size in the same industry